Emvistegrast is a quinolone derivative. Emvistegrast is an antagonist of α4β7 integrin. Emvistegrast can be studied in research for diseases that are mediated by α4β7 integrin, such as infkammatory bowel disease.

Disclosed in PCT patent WO2025/240833A1 from Acuitas Therapeutics Inc., Compound I‑1 is a trivalent tri-GalNAc PEGylated targeting lipid composed of three ASGPR-binding GalNAc moieties, a PEG spacer and double C18 alkyl lipid tails that insert into LNP lipid bilayer.

DSS6-PEG-DSPE,DSPE-PEG-DSS6 is a composite molecule composed of phospholipids(DSPE),polyethylene glycol(PEG),and bone targeting peptide DSS6,mainly used for bone targeted drug delivery and bone tissue repair. Its core structure achieves precise targeting and efficient delivery through the synergistic effect of three parts.The DSS6 peptide consists of six Asp-Ser-Ser amino acid repeat sequences and can specifically recognize hydroxyapatite(HAp)in bone tissue.

WEHI-7326 (WEHI 7326) is a specifi mitotic inhibitor and potential anticancer agent, causes cell cycle arrest in G2/M, cell death in vitro (MDA-MB-231 IC50=24.4 nM), and displays efficacious anti-tumor activity in vivo.WEHI-7326 induces cell death in a broad range of cancer cell lines, including taxane-resistant cells, and inhibits growth of human colon, brain, lung, prostate and breast tumors in mice xenografts.WEHI-7326 exceeded potency of myoseverin B by almost ten-fold, did not show any significant cytotoxic activity in vitro (IC50>40 uM) in HepG2 cells.WEHI-7326 prolongs survival in mouse models of high-risk neuroblastoma and leads to complete tumor regression when used in combination with standard-of-care relapse therapies.

HGT5001, disclosed in patent US 2026/0125339 A1 by Translate Bio (now part of Sanofi), is a novel ionizable cationic lipid optimized for mRNA delivery. It enables efficient LNP assembly, high mRNA encapsulation, potent endosomal escape, and exceptional in vivo protein expression, with demonstrated efficacy in therapeutic mRNA applications, low toxicity, and favorable biocompatibility, making it a leading candidate for advanced mRNA therapeutics.

AKG-UO-1 is a novel ionizable lipid. With excellent oxidative stability and efficient endosomal escape capability, it significantly improves mRNA delivery efficiency and vaccine stability, reduces degradation risks, making it an optimal component for lipid nanoparticles.

DSG-PEG2K-triGalNAc is a functionalized PEG lipid that enhances targeted drug delivery by binding to the Asialoglycoprotein Receptor (ASGPR) which are predominantly found on the surface of liver cells. By functionalizing DSG-PEG2K with triGalNac, it allows this PEG lipid to be used in the formation of liposomes or LNPs that target the liver for drug delivery.

MitoSOX Red is a live cell fluorescent probe that specifically targets mitochondria and is cell membrane permeable. MitoSOX Red enters mitochondria and is oxidized by superoxide but not by other ROS or RNS generating systems. The oxidized MitoSOX Red then binds to nucleic acids in mitochondria/nucleus, producing strong red fluorescence.

Anhydrotetracycline hydrochloride, a tetracycline biosynthetic precursor, is a potent competitive broad-spectrum tetracycline destructase enzymes inhibitor.

N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC50 = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC50 = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration.

A nonsteroidal selective estrogen receptor modulator (SERM) that shows 10- to 60-fold increased affinity for the estrogen receptor compared with Tamoxifen.

1400W dihydrochloride is a slow, tight binding, potent and highly selective inhibitor of inducible nitric oxide synthase (Kd = 7 nM).

Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system.

Chlorisondamine (diiodide) is a potent nicotinic acetylcholine receptor (nAChR) antagonist and a ganglion blocker. Chlorisondamine antagonizes some of nicotine's central actions in a potent, long-lasting and pharmacologically selective way.

N-C16-Deoxysphinganine is a biochemical reagent.

PSTC is a potent, selective Nrf2 activator with pEC50 of 7.7 (inducing of NQO1 specific enzyme activity).PSTC induces Nrf2 nuclear translocation, Nrf2-regulated gene expression, and downstream signaling events, including induction of NAD(P)H:NQO1 enzyme activity and heme oxygenase-1 protein expression, in an Nrf2-dependent manner.PSTC does not inhibit IL-1β-induced NF-κB translocation or insulin-induced S6 phosphorylation in human cells.PSTC restores oxidant (tert-butyl hydroperoxide) induced glutathione depletion in vitro and in vivo models of pulmonary oxidative stress.

MitoTracker Green FM is a green-fluorescent dye that can selectively accumulate in the mitochondrial matrix. MitoTracker Green FM covalently binds to mitochondrial proteins by reacting with free thiol groups of cysteine residues.

DSPE-PEG14-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

DMG-PEG2000-Biotin is a synthetic amphiphilic molecule composed of dimyristoyl glycerol (DMG), polyethylene glycol (PEG2000), and biotin functionalities. It is commonly employed in biomedical research for surface modification of lipid-based delivery platforms, such as lipid nanoparticles (LNPs) and liposomes. The PEG moiety enhances colloidal stability, prolongs circulation time, and reduces rapid clearance in vivo. The biotin termination facilitates conjugation to streptavidin-tagged biomolecules, exploiting the highly specific biotin-streptavidin interaction. Thus, DMG-PEG2000-Biotin is valuable for drug-delivery optimization, targeted therapeutic approaches, and in vitro diagnostic assay development.

Thiol-PEG2000-DMG is a phospholipid polyPEG which can be used to prepare liposomes or nanoparticles. The terminal thiol group reacts with maleimide, OPSS, vinylsulfone and transition metal surfaces including gold, silver, etc.

DMG-PEG2000-OH is a PEG derivative that can be used to construct drug delivery vehicles.

DMG-PEG2000-SH is a PEG derivative that can be used to construct drug delivery vehicles.

DMG-PEG2000-TCO offer the ability to easily conjugate to specific biomolecules via metal free click chemistry to tetrazines. By changing the PEG length, one can change the micelle size, immunological safety, and change the drug release rate.

DMG-PEG2000-NHS is a PEG derivative that can be used in various biomedical applications, such as the construction of drug delivery systems (siRNA delivery liposomes, lipid nanoparticle, etc.). The active ester (NHS) can react with an amino group (-NH2) to form a stable amide bond, which can be used as a linker in a bioconjugation strategy to modify amino-linked peptide proteins as well as other small molecules.

AGPS-IN-1a is a potent inhibitor of the ether lipid-generating enzyme alkyl-glycerone phosphate synthase (AGPS), selectively lowers ether lipid levels in several types of human cancer cells and impairs their cellular survival and migration..

KC‑34 (SPC‑A9) is a stereopure diketopiperazine‑based ionizable lipid from WO 2025/217299 A1 (PCT/US2025/023900) developed by Georgia Tech Research Corporation and Nava Therapeutics. It forms stable, well‑tolerated lipid nanoparticles (LNPs) that enable safe and efficient mRNA delivery to the liver, spleen, lung, and bone marrow in mice.

A10 (Compound 16) is a diketopiperazine‑based ionizable lipid disclosed in WO 2025/217298 A1 (PCT/US2025/023899) developed by NAVA Therapeutics that enables potent, cell‑selective in vivo delivery of mRNA and nucleic acids without targeting ligands. It forms stable, well‑tolerated lipid nanoparticles (LNPs) that preferentially transfect hematopoietic stem cells (HSCs), bone marrow progenitors, lung epithelium, endothelium, and immune cells while minimizing liver off‑target delivery. In both mice and non‑human primates, A10‑containing LNPs drive functional mRNA expression and gene editing in CD34⁺ HSCs at clinically relevant low doses (0.25–1.0 mg/kg), supporting in vivo HSC gene therapy without ex vivo manipulation.

Lipid 11 is the optimal ionizable lipid disclosed by Liberate Bio, Inc. in patent WO2025/250730 A1, which can significantly improve the delivery efficiency of nucleic acid drugs to extrahepatic tissues including bone marrow, spleen and muscle, with excellent in vivo stability and safety.

DEA‑14‑DAP is a novel ionizable cationic SORT lipid. As a key component for central nervous system targeting, it enables lipid nanoparticles (LNPs) to specifically target microglia, significantly improving the delivery efficiency and cellular selectivity of nucleic acid drugs in the brain.

AMXT-1501 tetrahydrochloride (AMXT 1501, AMXT1501) is a novel potent polyamine transport inhibitor, synergistically reduces cell viability in NB cells in combination with DFMO.